Last reviewed · How we verify

Genor Biopharma Co., Ltd. — Portfolio Competitive Intelligence Brief

Genor Biopharma Co., Ltd. pipeline: 0 marketed, 0 filed, 4 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 4 Phase 3 1 Phase 2 8 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
GB491+ Fulvestrant GB491+ Fulvestrant phase 3 Selective Estrogen Receptor Degrader (SERD) Estrogen Receptor (ER) Oncology
Placebo combined with Letrozole Placebo combined with Letrozole phase 3 Aromatase inhibitor Aromatase (CYP19A1) Oncology
GB242 GB242 phase 3 GLP-1 receptor agonist GLP-1R Diabetes
GB491 combined with Letrozole GB491 combined with Letrozole phase 3 CDK4/6 inhibitor (presumed) combined with aromatase inhibitor Oncology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Jiangsu HengRui Medicine Co., Ltd. · 3 shared drug classes
  2. AstraZeneca · 3 shared drug classes
  3. Hanmi Pharmaceutical Company Limited · 2 shared drug classes
  4. Pfizer · 2 shared drug classes
  5. Amsterdam UMC, location VUmc · 1 shared drug class
  6. Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh · 1 shared drug class
  7. Astellas Pharma Inc · 1 shared drug class
  8. Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Genor Biopharma Co., Ltd.:

Cite this brief

Drug Landscape (2026). Genor Biopharma Co., Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/genor-biopharma-co-ltd. Accessed 2026-05-16.

Related